Drug Type Antibody fusion proteins |
Synonyms |
Target |
Mechanism IL-15Rα modulators(Interleukin-15 receptor subunit alpha modulators), PDL1 inhibitors(Programmed death-ligand 1 inhibitors), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 17 Oct 2024 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 17 Oct 2024 | |
Kidney Neoplasms | Preclinical | CN | 01 Dec 2022 | |
Melanoma | Preclinical | CN | 01 Dec 2022 | |
Non-Small Cell Lung Cancer | Preclinical | CN | 01 Dec 2022 | |
Ovarian Cancer | Preclinical | CN | 01 Dec 2022 | |
Small Cell Lung Cancer | Preclinical | CN | 01 Dec 2022 |